Start-up company incorporated in as University of Porto spin-off developing innovative solutions to improve therapies, promoting healthier lives and well-being among patients with neuromuscular disorders.
What we're doing
InSignals is developing iHandU, the first technological solution for quantifying muscular rigidity in patients with neuromuscular disorders.
Our goal is to ensure the development of medical devices that reduce the subjectivity of neurological assessment, supporting clinicians and patients.
There’s a lack of solutions for quantitative evaluation of patients’ muscular rigidity.
There are millions of people worldwide suffering from neuromuscular disorders with muscle rigidity as one of the symptoms experienced.
The rigidity evaluation is important for physicians and patients as it is an indicator of disease progression and the efficacy of drugs and treatments.
iHandU can be a powerful tool to change this reality and eliminate the need for a subjective rigidity assessment.
iHandU aids in the management of neuromuscular disorders, starting with Parkinson’s Disease.
Reclaim the control
of your life
To track their symptoms and have more data regarding their disease, patients usually have at their disposal valuable tools:
We understand the importance of having a device that allows symptom tracking for better disease management. For this reason, a monitoring version of the iHandU device is being tested in a international Multi-centre Clinical Study. Patients using the monitoring version of iHandU will be able to:
For Neurologists and Neurosurgeons
iHandU has versatile characteristics that can be valuable in healthcare by providing more accurate care and contributing to a cost-effective service. Neurologists and neurosurgeons benefit from using this technology in several ways.
iHandU was designed after a challenge proposed by neurosurgeons treating Parkinson’s patients.
As confirmed by neurologists, there’s a lack of quantitative evaluation solutions of patient rigidity.
inSignals is already validating iHandU in the clinical setting, even in the exigent therapy of Deep Brain Stimulation. In Deep Brain Stimulation surgery physicians must verify the outcome of the therapy while in the operating room and without any instrument to support rigidity assessment for the optimum electrode implantation in the brain.Preliminary data from clinical studies indicate that iHandU improves the clinical outputs of Deep Brain stimulation to provide better patients’ quality of life.
The first version of iHandU, used in DBS surgery, was highly effective in assessing the rigidity improvement associated with optimal electrode placement.
We are extending the application of iHandU to monitor patients’ symptoms. Turning iHandU into a valuable remote patient monitoring (RPM) tool for neurologists to provide high-quality care for their patients promoting a personalized medicine.
With iHandU, it will be possible for physicians to:
Since the human brain is one of the most sophisticated systems in the world, researchers are still trying to understand how it works. Neurological diseases and movement disorders that impact the brain are both being researched, and there is still a lot to learn before humans can fully treat brain diseases.
The study of the brain, movement disorders, and physical symptoms are all intertwined. Having the assessment to one may open the door to a better understanding of the other.
At inSignals Neurotech we are concerned about contributing to the exploration of this essential subject. iHandU was also envisioned as a research instrument that could assist design a new future for the treatment and management of brain disorders.
iHandU is a valuable tool to help with gathering the scientific evidence of your project.
iHandU provides for the measurement of rigidity in patients with movement disorders, as well as the assessment of other physical complaints.
You can incorporate iHandU into your research for monitoring purposes or to explore the outcomes related to Deep Brain Stimulation surgeries.
iHandU can assist you in acquiring useful data from the assessment of physical symptoms reported by individuals with movement disorders in the monitoring context.
It can also be useful to confirm the efficacy and value of new pharmacological treatments and therapies for patients, ensuring that your solution is effective and beneficial to its users.
If you are promoting studies monitoring motor symptoms of neurological patients or studies in Deep Brain Stimulation, this is the right tool for your research.
We are neurotechnologists passionate to deliver better clinical outcomes
Wrist Rigidity Assessment during Deep Brain Stimulation Surgery (2015)
We designed a novel, comfortable and wireless wearable motion sensor to classify the wrist rigidity by deriving a robust signal descriptor from angular speed values and a polynomial mathematical model to classify signals using a quantitative continuous scale. The descriptor significantly (p<0.05) distinguished between non-rigid and rigid states, and the classification model labelled correctly 83.9% of the evaluated signals against the blind-agreement of two specialists. Additionally, we developed a methodology to detect cogwheel rigidity from the angular speed signal with high sensitivity (0.93). Our system provides a reliable evaluation of wrist rigidity, improving upon the inherent subjective clinical evaluation while using small, simple and easy to use motion sensors.
Presented and Published at the proceedings of the
37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society
MICo – Milano Conference Center
Milan, Italy, August 25-29 2015
An Adaptive model approach for quantitative wrist rigidity evaluation during Deep Brain Stimulation Surgery (2016)
To enhance the performance of the previously presented system, we aimed to develop models for high and low baseline rigidity, according to the examiner assessment before any stimulation. This would allow a more patient-oriented approach. Additionally, usability was improved by having in situ processing in a smartphone, instead of a computer. Such a system has shown to be reliable, presenting an accuracy of 82.0% and a mean error of 3.4%. Relatively to previous results, the performance was similar, further supporting the importance of considering the cogwheel rigidity to better infer about the reduction in rigidity. Overall, we present a simple, wearable, mobile system, suitable for intra-operatory conditions during DBS, supporting a physician in decision-making when setting stimulation parameters.
Presented and Published at the proceedings of the
38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society
Disney’s Contemporary Resort
Orlando, Florida (USA), August 16-20 2016
iHandU: Towards the validation of a wrist rigidity estimation for intraoperative DBS electrode position optimization (2019)
Our research group has previously designed a novel, a comfortable and wireless system aiming to tackle this subjectivity. This system comprised a gyroscope sensor in a textile band, placed in the patients’ hand, which communicated its measurement to a Smartphone via Bluetooth. During the wrist rigidity evaluation exam, a signal descriptor was computed from angular velocity (w) and a polynomial mathematical model was used to classify the signals using a quantitative scale of rigidity improvement. In this presented work, we aim to develop models that consider the 3-gyroscope-axes to acquire the w and the cogwheel rigidity. Our results showed that y-gyroscope-axis remains the best way to classify the reduction, showing an accuracy of 78% and a mean error of 3.5%. According to previous results, the performance was similar and the decrease of the samples to extract the w features did not compromise system performance. The cogwheel rigidity did not improve the previous model and other gyroscope-axis beyond the y-axis decreased system performance.
Presented and Published at the proceedings of the
9th International IEEE EMBS Conference on Neural Engineering
The Hilton Union Square
San Francisco, California (USA), March 20-23 2019
iHandU: A novel quantitative wrist rigidity evaluation device for deep brain stimulation surgery (2020)
In this work, we present a system that has seen four iterations since 2015, improving accuracy, usability and reliability. We aim to review the work done so far, outlining the iHandU system evolution, as well as the main challenges, lessons learned, and future steps to improve it. We also introduce the last version (iHandU 4.0), currently used in DBS surgeries at São João Hospital in Portugal.
Published at the proceedings of
Sensors – An Open Access Journal from MDPI
January 7 2020
They are supporting us.
Founders of inSignals Neurotech. Joined efforts with the ambition to develop and commercialise intellectual property related with iHandU technology to relevant industrial players.
INESC TEC is one of the most prestigious Portuguese research centres, specialised on computer science and systems engineering. Its core areas include biomedical engineering technologies, lead by Prof. João Paulo Cunha.
Prof. João Paulo Cunha is a innovator, inventor and passionate Professor of Bioengineering. He is driving the development of iHandU and progressing the development of a solution based on real medical inputs, to improve therapeutics when tackling neurological diseases.
Frontier IP Group Plc unites science and commerce by identifying strong intellectual property and accelerating its development. With a track record on business development, negotiation, licensing agreements and risk minimization, Frontier IP is dedicated to supporting science-based companies.
Frontier IP approach is focused on building value and provides proactive and hands-on support through its team to inSignals.
Funding & Investors
InSignals has received financial support from EIT Health and from Portugal Ventures to promote relevant business activities for the project.
EIT Health is a Knowledge and Innovation Community of the European Institute of Innovation and Technology (EIT). Through a unique collaborative approach, they are empowering a network of innovators to overcome barriers, challenge convention and take action to put innovative products and services into the hands of those that need them the most. inSignals has received the support from EIT Health since 2019.
Portugal Ventures has assumed a relevant role supporting inSignals. The Portuguese venture capital is supporting the grow of the national entrepreneurship ecosystem. With the ambition of boosting the global success of Portuguese companies, leading them to achieve competitiveness goals in all stages of their business development. In 2021 Portugal Ventures believed in the work developed by inSignals and joined us.
We are bringing to market a versatile tool for rigidity measurement, capable of improving the treatment and the lives of patients with neuromuscular disorders.
To demonstrate this, we are currently undergoing more clinical trials throughout Europe and US to confirm that our technology is successful.
Do you want to collaborate with us? Send us an email!
Copyright © 2022 inSignals Neurotech. All rights reserved.